 Joshua Thurman
Concepts (614)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 43 | 2024 | 318 | 11.180 |
Why?
| | Complement Activation | 62 | 2024 | 385 | 10.720 |
Why?
| | Kidney Diseases | 25 | 2024 | 382 | 9.190 |
Why?
| | Complement Pathway, Alternative | 35 | 2025 | 120 | 6.670 |
Why?
| | Complement Factor H | 17 | 2024 | 73 | 5.210 |
Why?
| | Complement Inactivating Agents | 14 | 2024 | 47 | 4.750 |
Why?
| | Kidney Glomerulus | 16 | 2024 | 109 | 4.290 |
Why?
| | Kidney | 31 | 2023 | 1382 | 4.210 |
Why?
| | Reperfusion Injury | 15 | 2019 | 272 | 3.980 |
Why?
| | Complement Factor B | 25 | 2023 | 109 | 3.810 |
Why?
| | Glomerulonephritis | 9 | 2023 | 46 | 3.740 |
Why?
| | Complement C3 | 25 | 2023 | 208 | 2.920 |
Why?
| | Immunoglobulin M | 9 | 2023 | 276 | 2.900 |
Why?
| | Glomerulosclerosis, Focal Segmental | 5 | 2022 | 43 | 2.530 |
Why?
| | Acute Kidney Injury | 13 | 2024 | 789 | 2.500 |
Why?
| | Autoimmune Diseases | 8 | 2023 | 428 | 2.360 |
Why?
| | Atypical Hemolytic Uremic Syndrome | 6 | 2023 | 19 | 2.060 |
Why?
| | Kidney Tubules | 8 | 2024 | 114 | 1.880 |
Why?
| | Receptor, Anaphylatoxin C5a | 7 | 2024 | 31 | 1.800 |
Why?
| | Receptors, Complement | 11 | 2022 | 122 | 1.690 |
Why?
| | Lupus Nephritis | 7 | 2021 | 49 | 1.680 |
Why?
| | Graft Rejection | 9 | 2019 | 598 | 1.620 |
Why?
| | Antibodies | 4 | 2024 | 398 | 1.580 |
Why?
| | Nephrosis, Lipoid | 2 | 2022 | 10 | 1.530 |
Why?
| | Nephrotic Syndrome | 2 | 2022 | 27 | 1.510 |
Why?
| | Mice | 75 | 2024 | 16973 | 1.420 |
Why?
| | Animals | 106 | 2025 | 35334 | 1.410 |
Why?
| | Endothelial Cells | 5 | 2022 | 739 | 1.380 |
Why?
| | Complement C3b | 4 | 2023 | 34 | 1.360 |
Why?
| | Inflammation | 16 | 2025 | 2741 | 1.330 |
Why?
| | Epitopes | 8 | 2023 | 473 | 1.320 |
Why?
| | Mice, Knockout | 34 | 2024 | 2887 | 1.300 |
Why?
| | Complement C3d | 9 | 2024 | 65 | 1.210 |
Why?
| | Immunosuppressive Agents | 6 | 2021 | 858 | 1.180 |
Why?
| | Complement Inactivator Proteins | 4 | 2021 | 41 | 1.170 |
Why?
| | Epithelial Cells | 10 | 2024 | 1061 | 1.160 |
Why?
| | Hemolytic-Uremic Syndrome | 4 | 2018 | 13 | 1.100 |
Why?
| | Antibodies, Monoclonal | 16 | 2023 | 1366 | 1.060 |
Why?
| | Contrast Media | 4 | 2018 | 393 | 1.050 |
Why?
| | Mice, Inbred C57BL | 44 | 2024 | 5468 | 1.030 |
Why?
| | Complement C5a | 7 | 2024 | 70 | 1.010 |
Why?
| | Glomerulonephritis, Membranoproliferative | 3 | 2023 | 13 | 1.010 |
Why?
| | Complement Pathway, Classical | 3 | 2021 | 19 | 0.980 |
Why?
| | Thrombotic Microangiopathies | 4 | 2018 | 15 | 0.950 |
Why?
| | Cell-Derived Microparticles | 2 | 2018 | 68 | 0.950 |
Why?
| | Humans | 98 | 2025 | 129527 | 0.930 |
Why?
| | Fluorescent Antibody Technique | 5 | 2021 | 376 | 0.920 |
Why?
| | Organ Transplantation | 2 | 2019 | 228 | 0.910 |
Why?
| | Endothelium, Vascular | 5 | 2020 | 895 | 0.840 |
Why?
| | Nephritis | 2 | 2013 | 22 | 0.810 |
Why?
| | Antigen-Antibody Complex | 3 | 2020 | 86 | 0.810 |
Why?
| | Lupus Erythematosus, Systemic | 8 | 2022 | 245 | 0.790 |
Why?
| | Kidney Transplantation | 8 | 2019 | 669 | 0.790 |
Why?
| | Angiogenesis Inducing Agents | 2 | 2021 | 23 | 0.780 |
Why?
| | Disease Models, Animal | 30 | 2024 | 4073 | 0.750 |
Why?
| | Magnetic Resonance Imaging | 5 | 2018 | 3392 | 0.740 |
Why?
| | Biomarkers | 17 | 2025 | 3968 | 0.720 |
Why?
| | Complement Membrane Attack Complex | 6 | 2018 | 37 | 0.720 |
Why?
| | Rhabdomyolysis | 1 | 2021 | 21 | 0.710 |
Why?
| | Cardiolipins | 1 | 2021 | 83 | 0.710 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 391 | 0.690 |
Why?
| | Otitis Media | 5 | 2016 | 160 | 0.630 |
Why?
| | Immunoglobulin G | 11 | 2023 | 851 | 0.630 |
Why?
| | Cyclosporine | 3 | 2019 | 263 | 0.620 |
Why?
| | Hemoglobinuria, Paroxysmal | 2 | 2020 | 6 | 0.620 |
Why?
| | Vascular System Injuries | 1 | 2019 | 73 | 0.610 |
Why?
| | Retinal Pigment Epithelium | 4 | 2017 | 70 | 0.610 |
Why?
| | Kidney Failure, Chronic | 3 | 2021 | 546 | 0.600 |
Why?
| | Complement Factor D | 1 | 2018 | 30 | 0.590 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 755 | 0.580 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2020 | 270 | 0.570 |
Why?
| | Pneumococcal Infections | 4 | 2014 | 112 | 0.570 |
Why?
| | Autoantibodies | 10 | 2023 | 1468 | 0.560 |
Why?
| | Glomerulonephritis, IGA | 1 | 2017 | 10 | 0.560 |
Why?
| | Doxorubicin | 4 | 2023 | 328 | 0.560 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 417 | 0.550 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2025 | 566 | 0.540 |
Why?
| | Transplantation, Homologous | 3 | 2019 | 402 | 0.540 |
Why?
| | B-Lymphocytes | 7 | 2022 | 816 | 0.540 |
Why?
| | Rheumatic Diseases | 1 | 2017 | 69 | 0.530 |
Why?
| | Annexin A2 | 1 | 2016 | 10 | 0.500 |
Why?
| | Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 86 | 0.500 |
Why?
| | Renal Insufficiency | 1 | 2018 | 149 | 0.500 |
Why?
| | Streptococcus pneumoniae | 4 | 2014 | 161 | 0.480 |
Why?
| | Liver Neoplasms | 1 | 2020 | 635 | 0.470 |
Why?
| | Peptide Fragments | 1 | 2019 | 695 | 0.470 |
Why?
| | Mice, Inbred BALB C | 10 | 2023 | 1248 | 0.460 |
Why?
| | Pregnancy Complications | 3 | 2018 | 493 | 0.460 |
Why?
| | Complement C3a | 4 | 2024 | 41 | 0.450 |
Why?
| | Magnetite Nanoparticles | 2 | 2011 | 29 | 0.450 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2020 | 1327 | 0.450 |
Why?
| | Male | 48 | 2024 | 63586 | 0.440 |
Why?
| | Cardiac Surgical Procedures | 1 | 2019 | 509 | 0.430 |
Why?
| | Immune Complex Diseases | 1 | 2012 | 7 | 0.410 |
Why?
| | Female | 43 | 2024 | 68650 | 0.390 |
Why?
| | Autoimmunity | 5 | 2022 | 863 | 0.390 |
Why?
| | Receptors, Complement 3b | 6 | 2016 | 84 | 0.390 |
Why?
| | Peptides, Cyclic | 1 | 2014 | 256 | 0.390 |
Why?
| | Liver | 2 | 2020 | 1836 | 0.390 |
Why?
| | Immunity, Humoral | 1 | 2013 | 118 | 0.390 |
Why?
| | Molecular Imaging | 1 | 2012 | 54 | 0.380 |
Why?
| | Nanoparticles | 2 | 2013 | 376 | 0.380 |
Why?
| | Complement C1q | 3 | 2014 | 37 | 0.370 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 113 | 0.370 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2019 | 836 | 0.360 |
Why?
| | Oxidative Stress | 8 | 2024 | 1261 | 0.360 |
Why?
| | Complement C2 | 2 | 2011 | 7 | 0.360 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 264 | 0.330 |
Why?
| | CD55 Antigens | 3 | 2020 | 30 | 0.330 |
Why?
| | Blotting, Western | 7 | 2016 | 1199 | 0.330 |
Why?
| | Ferrosoferric Oxide | 1 | 2010 | 26 | 0.330 |
Why?
| | B-Lymphocyte Subsets | 1 | 2010 | 74 | 0.330 |
Why?
| | Cell Membrane | 4 | 2022 | 733 | 0.330 |
Why?
| | Plasmodium falciparum | 3 | 1998 | 30 | 0.320 |
Why?
| | Disease Susceptibility | 2 | 2020 | 333 | 0.320 |
Why?
| | Protozoan Proteins | 3 | 1998 | 75 | 0.310 |
Why?
| | Properdin | 2 | 2020 | 9 | 0.300 |
Why?
| | Diarrhea | 1 | 2009 | 180 | 0.300 |
Why?
| | Antibody Specificity | 2 | 2021 | 184 | 0.300 |
Why?
| | Cytokines | 5 | 2019 | 2018 | 0.300 |
Why?
| | Signal Transduction | 9 | 2020 | 4916 | 0.290 |
Why?
| | Epidermolysis Bullosa Acquisita | 3 | 2018 | 6 | 0.290 |
Why?
| | Complement C4 | 5 | 2021 | 25 | 0.290 |
Why?
| | Receptors, Complement 3d | 4 | 2022 | 141 | 0.290 |
Why?
| | Uremia | 2 | 2021 | 14 | 0.280 |
Why?
| | Disease Progression | 6 | 2025 | 2628 | 0.280 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2008 | 68 | 0.280 |
Why?
| | Blood Platelets | 2 | 2024 | 386 | 0.280 |
Why?
| | Phagocytosis | 4 | 2023 | 362 | 0.280 |
Why?
| | Complement C3b Inactivator Proteins | 2 | 2017 | 9 | 0.280 |
Why?
| | Graft Survival | 4 | 2019 | 514 | 0.270 |
Why?
| | Adult | 13 | 2023 | 35505 | 0.270 |
Why?
| | Podocytes | 2 | 2020 | 52 | 0.270 |
Why?
| | Chemokines, CXC | 1 | 2007 | 70 | 0.270 |
Why?
| | Adaptive Immunity | 2 | 2019 | 161 | 0.260 |
Why?
| | Kidney Tubules, Proximal | 2 | 2016 | 125 | 0.260 |
Why?
| | Metabolomics | 4 | 2019 | 652 | 0.260 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2007 | 123 | 0.260 |
Why?
| | Cells, Cultured | 6 | 2019 | 4087 | 0.260 |
Why?
| | Flow Cytometry | 4 | 2022 | 1158 | 0.250 |
Why?
| | Pilot Projects | 3 | 2021 | 1594 | 0.250 |
Why?
| | Chemokines | 1 | 2007 | 227 | 0.250 |
Why?
| | Cardiopulmonary Bypass | 1 | 2008 | 203 | 0.250 |
Why?
| | Immune System Diseases | 1 | 2006 | 34 | 0.250 |
Why?
| | Immunohistochemistry | 5 | 2016 | 1684 | 0.250 |
Why?
| | Protein Binding | 6 | 2019 | 2121 | 0.240 |
Why?
| | NF-kappa B | 3 | 2016 | 666 | 0.240 |
Why?
| | Rats | 9 | 2024 | 5470 | 0.240 |
Why?
| | Organ Specificity | 3 | 2020 | 296 | 0.240 |
Why?
| | Cell Line | 6 | 2017 | 2774 | 0.240 |
Why?
| | Biopsy | 3 | 2019 | 1087 | 0.230 |
Why?
| | Kidney Tubular Necrosis, Acute | 1 | 2005 | 26 | 0.230 |
Why?
| | Caspases | 1 | 2006 | 245 | 0.230 |
Why?
| | Fetal Death | 1 | 2005 | 55 | 0.230 |
Why?
| | Antibodies, Antiphospholipid | 1 | 2005 | 26 | 0.230 |
Why?
| | Tandem Mass Spectrometry | 3 | 2019 | 525 | 0.230 |
Why?
| | Macular Degeneration | 3 | 2012 | 159 | 0.220 |
Why?
| | Complement C3-C5 Convertases | 3 | 2016 | 23 | 0.220 |
Why?
| | Child | 11 | 2023 | 20932 | 0.220 |
Why?
| | Immunity, Innate | 6 | 2017 | 804 | 0.220 |
Why?
| | Chromatography, Liquid | 2 | 2016 | 424 | 0.220 |
Why?
| | Platelet Activation | 1 | 2024 | 91 | 0.220 |
Why?
| | Antibodies, Protozoan | 3 | 1998 | 32 | 0.220 |
Why?
| | Receptors, Angiotensin | 1 | 2003 | 12 | 0.210 |
Why?
| | Mice, Inbred MRL lpr | 4 | 2022 | 38 | 0.210 |
Why?
| | Prognosis | 5 | 2022 | 3772 | 0.200 |
Why?
| | Middle Aged | 10 | 2022 | 31087 | 0.200 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2003 | 89 | 0.200 |
Why?
| | Ischemia | 3 | 2015 | 405 | 0.200 |
Why?
| | Tacrolimus | 2 | 2014 | 193 | 0.190 |
Why?
| | Case-Control Studies | 2 | 2021 | 3383 | 0.190 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 197 | 0.190 |
Why?
| | Allografts | 2 | 2019 | 137 | 0.190 |
Why?
| | Lymphoid Tissue | 1 | 2022 | 67 | 0.190 |
Why?
| | CD59 Antigens | 3 | 2011 | 20 | 0.190 |
Why?
| | Proteomics | 4 | 2018 | 1053 | 0.190 |
Why?
| | Antigens, Protozoan | 2 | 1998 | 22 | 0.180 |
Why?
| | Apoptosis | 2 | 2011 | 2488 | 0.180 |
Why?
| | Organic Anion Transporters | 1 | 2021 | 16 | 0.180 |
Why?
| | Myoglobin | 1 | 2021 | 12 | 0.180 |
Why?
| | Immune System | 1 | 2022 | 174 | 0.180 |
Why?
| | Malaria, Falciparum | 2 | 1998 | 27 | 0.180 |
Why?
| | Glutamic Acid | 1 | 2023 | 235 | 0.180 |
Why?
| | Protein Processing, Post-Translational | 3 | 2023 | 456 | 0.180 |
Why?
| | Proteinuria | 3 | 2012 | 91 | 0.180 |
Why?
| | Choroidal Neovascularization | 2 | 2013 | 55 | 0.180 |
Why?
| | Frozen Sections | 1 | 2021 | 26 | 0.180 |
Why?
| | Paraffin Embedding | 1 | 2021 | 29 | 0.170 |
Why?
| | Hypertension, Pulmonary | 2 | 2024 | 1891 | 0.170 |
Why?
| | Anemia, Hemolytic | 1 | 2020 | 16 | 0.170 |
Why?
| | Albuminuria | 2 | 2015 | 183 | 0.170 |
Why?
| | Formaldehyde | 1 | 2021 | 59 | 0.170 |
Why?
| | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2020 | 23 | 0.170 |
Why?
| | Staining and Labeling | 1 | 2021 | 143 | 0.170 |
Why?
| | Extracellular Vesicles | 1 | 2022 | 129 | 0.170 |
Why?
| | Dendritic Cells | 2 | 2022 | 481 | 0.170 |
Why?
| | Aged | 7 | 2021 | 22063 | 0.170 |
Why?
| | Lung | 6 | 2024 | 3928 | 0.170 |
Why?
| | Up-Regulation | 3 | 2019 | 832 | 0.170 |
Why?
| | Treatment Outcome | 3 | 2021 | 10232 | 0.160 |
Why?
| | Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 10 | 0.160 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2012 | 527 | 0.160 |
Why?
| | Transplantation, Heterologous | 1 | 2019 | 190 | 0.160 |
Why?
| | Critical Illness | 2 | 2023 | 758 | 0.160 |
Why?
| | T-Lymphocytes | 5 | 2022 | 1935 | 0.160 |
Why?
| | Urinalysis | 1 | 2019 | 75 | 0.160 |
Why?
| | Pharmaceutical Preparations | 1 | 2021 | 168 | 0.150 |
Why?
| | Iodine Radioisotopes | 1 | 2019 | 140 | 0.150 |
Why?
| | Sepsis | 2 | 2016 | 576 | 0.150 |
Why?
| | Complement C4a | 1 | 2018 | 9 | 0.150 |
Why?
| | North America | 1 | 2019 | 294 | 0.150 |
Why?
| | Complement C5 | 3 | 2020 | 78 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 952 | 0.150 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2734 | 0.150 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2018 | 12 | 0.140 |
Why?
| | Granulocytes | 2 | 2016 | 77 | 0.140 |
Why?
| | Vascular Remodeling | 1 | 2020 | 189 | 0.140 |
Why?
| | HLA Antigens | 1 | 2019 | 235 | 0.140 |
Why?
| | Organelles | 1 | 1998 | 54 | 0.140 |
Why?
| | Erythrocytes | 2 | 2020 | 673 | 0.140 |
Why?
| | Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2017 | 35 | 0.140 |
Why?
| | Complement Pathway, Mannose-Binding Lectin | 1 | 2017 | 26 | 0.140 |
Why?
| | Brain Injuries | 3 | 2007 | 469 | 0.140 |
Why?
| | Gene Expression | 6 | 2017 | 1461 | 0.140 |
Why?
| | Cyclophilins | 1 | 2017 | 40 | 0.140 |
Why?
| | Adolescent | 7 | 2021 | 20409 | 0.140 |
Why?
| | Brachial Artery | 1 | 2018 | 192 | 0.130 |
Why?
| | Diethylhexyl Phthalate | 1 | 2017 | 15 | 0.130 |
Why?
| | Glomerular Filtration Rate | 2 | 2018 | 711 | 0.130 |
Why?
| | Cell Differentiation | 2 | 2022 | 1895 | 0.130 |
Why?
| | Choroiditis | 1 | 2016 | 6 | 0.130 |
Why?
| | Lipopolysaccharides | 3 | 2015 | 872 | 0.130 |
Why?
| | Interferon-beta | 2 | 2007 | 89 | 0.130 |
Why?
| | Bleomycin | 1 | 2018 | 243 | 0.130 |
Why?
| | Arthritis, Experimental | 2 | 2009 | 135 | 0.130 |
Why?
| | Cell Aggregation | 1 | 2016 | 26 | 0.130 |
Why?
| | Benzhydryl Compounds | 1 | 2017 | 66 | 0.130 |
Why?
| | Mitochondria | 2 | 2024 | 876 | 0.130 |
Why?
| | Phenols | 1 | 2017 | 97 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 1001 | 0.130 |
Why?
| | Blood Pressure | 1 | 2003 | 1735 | 0.130 |
Why?
| | Ear, Middle | 3 | 2012 | 91 | 0.130 |
Why?
| | Tuberculosis | 1 | 2019 | 273 | 0.120 |
Why?
| | Macrophages | 3 | 2013 | 1486 | 0.120 |
Why?
| | Prospective Studies | 4 | 2023 | 7150 | 0.120 |
Why?
| | Collagen Type VII | 3 | 2018 | 27 | 0.120 |
Why?
| | Complement C5b | 1 | 2015 | 5 | 0.120 |
Why?
| | Mycobacterium tuberculosis | 1 | 2019 | 309 | 0.120 |
Why?
| | Mucin-5B | 1 | 2018 | 215 | 0.120 |
Why?
| | Interferon-alpha | 2 | 2007 | 194 | 0.120 |
Why?
| | Carboxypeptidases | 1 | 2015 | 13 | 0.120 |
Why?
| | MicroRNAs | 1 | 2022 | 677 | 0.120 |
Why?
| | Immunoprecipitation | 1 | 2016 | 154 | 0.120 |
Why?
| | Inflammation Mediators | 3 | 2019 | 503 | 0.120 |
Why?
| | Hypersensitivity, Delayed | 1 | 2015 | 28 | 0.120 |
Why?
| | Oncolytic Viruses | 1 | 2015 | 7 | 0.120 |
Why?
| | Oncolytic Virotherapy | 1 | 2015 | 13 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 100 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 427 | 0.120 |
Why?
| | Analysis of Variance | 2 | 2010 | 1286 | 0.120 |
Why?
| | Vaccinia virus | 1 | 2015 | 42 | 0.120 |
Why?
| | Vasodilation | 1 | 2018 | 476 | 0.120 |
Why?
| | Complement Fixation Tests | 1 | 2014 | 6 | 0.120 |
Why?
| | Ultrasonography | 1 | 2018 | 708 | 0.120 |
Why?
| | Fibroblasts | 1 | 2020 | 943 | 0.110 |
Why?
| | Urinary Tract Infections | 1 | 2016 | 151 | 0.110 |
Why?
| | Recombinant Proteins | 3 | 2015 | 1311 | 0.110 |
Why?
| | Abortion, Spontaneous | 2 | 2006 | 100 | 0.110 |
Why?
| | Shiga Toxin 2 | 1 | 2014 | 1 | 0.110 |
Why?
| | Edema | 1 | 2015 | 124 | 0.110 |
Why?
| | Eustachian Tube | 1 | 2014 | 8 | 0.110 |
Why?
| | Hypertension | 1 | 2003 | 1235 | 0.110 |
Why?
| | Mesangial Cells | 1 | 2013 | 4 | 0.110 |
Why?
| | Models, Immunological | 2 | 2012 | 96 | 0.110 |
Why?
| | Immunoglobulins | 2 | 2020 | 162 | 0.110 |
Why?
| | Mast Cells | 1 | 2015 | 142 | 0.110 |
Why?
| | Neutrophils | 2 | 2013 | 1209 | 0.110 |
Why?
| | Orthomyxoviridae Infections | 1 | 2014 | 67 | 0.110 |
Why?
| | Aquaporins | 2 | 2003 | 8 | 0.100 |
Why?
| | Diagnostic Imaging | 1 | 2016 | 326 | 0.100 |
Why?
| | Cricetulus | 2 | 2010 | 107 | 0.100 |
Why?
| | Mycophenolic Acid | 1 | 2014 | 110 | 0.100 |
Why?
| | CHO Cells | 2 | 2010 | 155 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 412 | 0.100 |
Why?
| | Recurrence | 1 | 2016 | 1011 | 0.100 |
Why?
| | Cricetinae | 2 | 2010 | 280 | 0.100 |
Why?
| | Serum | 1 | 2013 | 58 | 0.100 |
Why?
| | Genetic Variation | 1 | 2018 | 936 | 0.100 |
Why?
| | Genotype | 1 | 2018 | 1827 | 0.100 |
Why?
| | Acute Disease | 3 | 2014 | 975 | 0.100 |
Why?
| | Surface Plasmon Resonance | 1 | 2013 | 88 | 0.100 |
Why?
| | Embryo, Nonmammalian | 1 | 2013 | 166 | 0.100 |
Why?
| | Lymphocyte Activation | 5 | 2022 | 1109 | 0.100 |
Why?
| | Sodium Chloride, Dietary | 1 | 2012 | 31 | 0.100 |
Why?
| | Lymphocyte Depletion | 1 | 2013 | 134 | 0.100 |
Why?
| | Amino Acids | 1 | 2016 | 487 | 0.100 |
Why?
| | Acute Lung Injury | 1 | 2015 | 280 | 0.100 |
Why?
| | Mass Spectrometry | 1 | 2016 | 717 | 0.100 |
Why?
| | Encephalomyelitis, Autoimmune, Experimental | 1 | 2013 | 62 | 0.100 |
Why?
| | Ultraviolet Rays | 1 | 2015 | 383 | 0.100 |
Why?
| | Macrophages, Alveolar | 1 | 2015 | 389 | 0.100 |
Why?
| | Skin | 2 | 2015 | 724 | 0.100 |
Why?
| | Pregnancy | 4 | 2018 | 6412 | 0.100 |
Why?
| | Rhadinovirus | 1 | 2012 | 20 | 0.100 |
Why?
| | Drug Monitoring | 1 | 2013 | 214 | 0.100 |
Why?
| | Sirolimus | 1 | 2014 | 270 | 0.100 |
Why?
| | Recombinant Fusion Proteins | 2 | 2009 | 650 | 0.100 |
Why?
| | Tumor Virus Infections | 1 | 2012 | 46 | 0.090 |
Why?
| | Rituximab | 1 | 2013 | 164 | 0.090 |
Why?
| | Myocytes, Cardiac | 2 | 2013 | 492 | 0.090 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2017 | 1058 | 0.090 |
Why?
| | Extracellular Fluid | 1 | 2011 | 30 | 0.090 |
Why?
| | Bronchial Hyperreactivity | 1 | 2011 | 109 | 0.090 |
Why?
| | Spleen | 1 | 2013 | 508 | 0.090 |
Why?
| | Herpesviridae Infections | 1 | 2012 | 142 | 0.090 |
Why?
| | Tissue Distribution | 3 | 2019 | 315 | 0.090 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2018 | 634 | 0.090 |
Why?
| | Plasma Exchange | 1 | 2010 | 12 | 0.090 |
Why?
| | Adenocarcinoma | 1 | 2017 | 889 | 0.090 |
Why?
| | Down-Regulation | 4 | 2020 | 631 | 0.090 |
Why?
| | Feasibility Studies | 2 | 2015 | 869 | 0.090 |
Why?
| | In Situ Nick-End Labeling | 1 | 2010 | 123 | 0.090 |
Why?
| | Blister | 2 | 2008 | 41 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1422 | 0.080 |
Why?
| | Blood Bactericidal Activity | 1 | 2010 | 36 | 0.080 |
Why?
| | Membrane Cofactor Protein | 1 | 2010 | 13 | 0.080 |
Why?
| | Opsonin Proteins | 1 | 2010 | 25 | 0.080 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 118 | 0.080 |
Why?
| | Dextrans | 1 | 2010 | 83 | 0.080 |
Why?
| | Collagen Type II | 1 | 2009 | 48 | 0.080 |
Why?
| | Osteoarthritis | 1 | 2011 | 168 | 0.080 |
Why?
| | Microbial Viability | 1 | 2010 | 83 | 0.080 |
Why?
| | Time Factors | 4 | 2015 | 6530 | 0.080 |
Why?
| | Host-Pathogen Interactions | 1 | 2012 | 355 | 0.080 |
Why?
| | Image Enhancement | 1 | 2010 | 167 | 0.080 |
Why?
| | Antibody Formation | 1 | 2010 | 291 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 1 | 2018 | 2503 | 0.080 |
Why?
| | RNA, Messenger | 6 | 2022 | 2697 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2010 | 397 | 0.080 |
Why?
| | Cell Hypoxia | 1 | 2010 | 226 | 0.080 |
Why?
| | Allergens | 1 | 2011 | 385 | 0.070 |
Why?
| | Insulin Resistance | 1 | 2017 | 1168 | 0.070 |
Why?
| | Bacillus cereus | 1 | 2008 | 5 | 0.070 |
Why?
| | Blood-Retinal Barrier | 1 | 2008 | 14 | 0.070 |
Why?
| | Liver Regeneration | 1 | 2008 | 40 | 0.070 |
Why?
| | Bacteremia | 1 | 2010 | 194 | 0.070 |
Why?
| | Receptor, Interferon alpha-beta | 1 | 2007 | 33 | 0.070 |
Why?
| | Hemolysis | 2 | 2020 | 199 | 0.070 |
Why?
| | Bronchiolitis Obliterans | 1 | 2007 | 68 | 0.070 |
Why?
| | Neurons | 2 | 2006 | 1509 | 0.070 |
Why?
| | Binding Sites | 3 | 2016 | 1250 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 4 | 2010 | 2271 | 0.070 |
Why?
| | Young Adult | 2 | 2021 | 12438 | 0.070 |
Why?
| | Chemokine CXCL2 | 1 | 2007 | 43 | 0.070 |
Why?
| | Gene Expression Profiling | 3 | 2011 | 1684 | 0.070 |
Why?
| | Chemokine CXCL1 | 1 | 2007 | 72 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 152 | 0.070 |
Why?
| | Cloning, Molecular | 2 | 2017 | 524 | 0.070 |
Why?
| | Kidney Concentrating Ability | 2 | 2003 | 3 | 0.070 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2009 | 185 | 0.060 |
Why?
| | Poly I-C | 1 | 2006 | 62 | 0.060 |
Why?
| | Immunization, Passive | 1 | 2006 | 86 | 0.060 |
Why?
| | Leukocytes | 1 | 2008 | 304 | 0.060 |
Why?
| | Renal Circulation | 1 | 2006 | 57 | 0.060 |
Why?
| | Respiratory Hypersensitivity | 1 | 2006 | 65 | 0.060 |
Why?
| | Antigens, Surface | 1 | 2006 | 152 | 0.060 |
Why?
| | Nephrectomy | 1 | 2006 | 158 | 0.060 |
Why?
| | Renal Dialysis | 1 | 2009 | 423 | 0.060 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2010 | 739 | 0.060 |
Why?
| | Complement C6 | 2 | 2018 | 9 | 0.060 |
Why?
| | Mice, Transgenic | 3 | 2017 | 2135 | 0.060 |
Why?
| | Rats, Sprague-Dawley | 3 | 2006 | 2393 | 0.060 |
Why?
| | Nitric Oxide | 1 | 2010 | 897 | 0.060 |
Why?
| | Placental Insufficiency | 1 | 2006 | 112 | 0.060 |
Why?
| | Basement Membrane | 1 | 2005 | 32 | 0.060 |
Why?
| | Mutation | 1 | 2016 | 3702 | 0.060 |
Why?
| | Membrane Transport Proteins | 2 | 2003 | 149 | 0.060 |
Why?
| | Random Allocation | 1 | 2006 | 344 | 0.060 |
Why?
| | Probability | 1 | 2006 | 302 | 0.060 |
Why?
| | Chromatography, High Pressure Liquid | 2 | 2019 | 584 | 0.060 |
Why?
| | Neuroprotective Agents | 1 | 2006 | 121 | 0.060 |
Why?
| | Aristolochic Acids | 1 | 2024 | 1 | 0.060 |
Why?
| | Lung Transplantation | 1 | 2007 | 290 | 0.060 |
Why?
| | Pregnancy Complications, Hematologic | 1 | 2005 | 20 | 0.060 |
Why?
| | Lung Neoplasms | 1 | 2017 | 2342 | 0.060 |
Why?
| | Epitope Mapping | 1 | 2005 | 58 | 0.060 |
Why?
| | Schistosoma | 1 | 2024 | 28 | 0.060 |
Why?
| | Schistosomiasis | 1 | 2024 | 47 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3150 | 0.050 |
Why?
| | Collagen | 1 | 2006 | 436 | 0.050 |
Why?
| | Toll-Like Receptors | 2 | 2016 | 179 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2010 | 1118 | 0.050 |
Why?
| | Lung Injury | 1 | 2006 | 211 | 0.050 |
Why?
| | Brain | 2 | 2006 | 2675 | 0.050 |
Why?
| | Pulmonary Fibrosis | 1 | 2007 | 385 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2006 | 381 | 0.050 |
Why?
| | Myocardium | 1 | 2009 | 981 | 0.050 |
Why?
| | Drinking Behavior | 1 | 2003 | 11 | 0.050 |
Why?
| | Compulsive Behavior | 1 | 2003 | 7 | 0.050 |
Why?
| | Annexins | 1 | 2023 | 3 | 0.050 |
Why?
| | Racemethionine | 1 | 2023 | 3 | 0.050 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2003 | 22 | 0.050 |
Why?
| | Antiphospholipid Syndrome | 1 | 2003 | 37 | 0.050 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 2003 | 9 | 0.050 |
Why?
| | Folic Acid | 1 | 2024 | 182 | 0.050 |
Why?
| | Complement C9 | 1 | 2003 | 5 | 0.050 |
Why?
| | Myelin-Oligodendrocyte Glycoprotein | 1 | 2023 | 50 | 0.050 |
Why?
| | Blood Urea Nitrogen | 1 | 2003 | 53 | 0.050 |
Why?
| | Mutagenesis, Site-Directed | 2 | 2016 | 363 | 0.050 |
Why?
| | Cartilage, Articular | 1 | 2006 | 292 | 0.050 |
Why?
| | Congresses as Topic | 1 | 2024 | 215 | 0.050 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2010 | 2062 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2023 | 220 | 0.050 |
Why?
| | Energy Metabolism | 2 | 2019 | 864 | 0.050 |
Why?
| | Hypothyroidism | 1 | 2003 | 66 | 0.050 |
Why?
| | Sodium | 1 | 2003 | 204 | 0.050 |
Why?
| | Methionine | 1 | 2023 | 154 | 0.050 |
Why?
| | Carrier Proteins | 2 | 2003 | 740 | 0.050 |
Why?
| | Neutralization Tests | 2 | 2015 | 73 | 0.050 |
Why?
| | Immunoglobulin Isotypes | 1 | 2022 | 34 | 0.050 |
Why?
| | HLA-D Antigens | 1 | 2022 | 34 | 0.050 |
Why?
| | Ubiquitination | 1 | 2022 | 98 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2022 | 271 | 0.050 |
Why?
| | Imatinib Mesylate | 1 | 2021 | 75 | 0.050 |
Why?
| | Phospholipase D | 1 | 2020 | 8 | 0.040 |
Why?
| | Cholecalciferol | 1 | 2021 | 56 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2022 | 207 | 0.040 |
Why?
| | Fetal Growth Retardation | 1 | 2006 | 549 | 0.040 |
Why?
| | Ubiquitin-Protein Ligases | 1 | 2022 | 157 | 0.040 |
Why?
| | Amino Acid Sequence | 2 | 2010 | 2055 | 0.040 |
Why?
| | Antibodies, Blocking | 1 | 2020 | 33 | 0.040 |
Why?
| | Cell Line, Transformed | 1 | 2020 | 139 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2022 | 363 | 0.040 |
Why?
| | Drug Therapy, Combination | 1 | 2003 | 1037 | 0.040 |
Why?
| | Particle Size | 1 | 2021 | 354 | 0.040 |
Why?
| | Reactive Oxygen Species | 2 | 2013 | 591 | 0.040 |
Why?
| | Cell Movement | 2 | 2015 | 942 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2020 | 99 | 0.040 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2020 | 101 | 0.040 |
Why?
| | Child, Preschool | 2 | 2015 | 10499 | 0.040 |
Why?
| | Mice, Congenic | 2 | 2010 | 22 | 0.040 |
Why?
| | Dinoprost | 1 | 2019 | 44 | 0.040 |
Why?
| | Mice, 129 Strain | 1 | 2019 | 87 | 0.040 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2020 | 147 | 0.040 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2020 | 182 | 0.040 |
Why?
| | Cell Line, Tumor | 2 | 2017 | 3181 | 0.040 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2015 | 646 | 0.040 |
Why?
| | Immunoblotting | 2 | 2010 | 303 | 0.040 |
Why?
| | Epitopes, T-Lymphocyte | 1 | 2019 | 186 | 0.040 |
Why?
| | Brefeldin A | 1 | 1998 | 10 | 0.040 |
Why?
| | Interleukin-1beta | 1 | 2020 | 368 | 0.040 |
Why?
| | Gene Knockdown Techniques | 1 | 2019 | 315 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 1998 | 52 | 0.040 |
Why?
| | Cyclopentanes | 1 | 1998 | 19 | 0.040 |
Why?
| | Immunity, Active | 1 | 1998 | 10 | 0.040 |
Why?
| | A549 Cells | 1 | 2018 | 59 | 0.040 |
Why?
| | Aotidae | 1 | 1998 | 7 | 0.040 |
Why?
| | Protein Synthesis Inhibitors | 1 | 1998 | 41 | 0.040 |
Why?
| | Parasitemia | 1 | 1998 | 11 | 0.040 |
Why?
| | Immunodominant Epitopes | 1 | 1998 | 28 | 0.040 |
Why?
| | Self Tolerance | 1 | 2017 | 28 | 0.040 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 408 | 0.040 |
Why?
| | Macrolides | 1 | 1998 | 60 | 0.040 |
Why?
| | Immunologic Deficiency Syndromes | 1 | 2018 | 64 | 0.040 |
Why?
| | Vitamin D | 1 | 2021 | 379 | 0.040 |
Why?
| | Ligands | 1 | 2019 | 619 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 1998 | 371 | 0.030 |
Why?
| | Immunomodulation | 1 | 2017 | 92 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2017 | 150 | 0.030 |
Why?
| | Recombination, Genetic | 1 | 1998 | 187 | 0.030 |
Why?
| | DNA Damage | 1 | 2019 | 383 | 0.030 |
Why?
| | Germinal Center | 1 | 2017 | 57 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2017 | 183 | 0.030 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 1203 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2021 | 737 | 0.030 |
Why?
| | T-Box Domain Proteins | 1 | 2017 | 96 | 0.030 |
Why?
| | Biological Transport, Active | 1 | 2016 | 78 | 0.030 |
Why?
| | Epithelial Sodium Channels | 1 | 2016 | 19 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Infant | 1 | 2009 | 9005 | 0.030 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2017 | 200 | 0.030 |
Why?
| | Sulfones | 1 | 2016 | 108 | 0.030 |
Why?
| | Protein Kinases | 1 | 2017 | 314 | 0.030 |
Why?
| | Nitriles | 1 | 2016 | 169 | 0.030 |
Why?
| | Potassium Channels | 1 | 2016 | 149 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2015 | 33 | 0.030 |
Why?
| | Smallpox Vaccine | 1 | 2015 | 23 | 0.030 |
Why?
| | Macaca fascicularis | 1 | 2015 | 63 | 0.030 |
Why?
| | Vero Cells | 1 | 2015 | 66 | 0.030 |
Why?
| | Sunburn | 1 | 2015 | 26 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 232 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 224 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2017 | 804 | 0.030 |
Why?
| | Fetus | 2 | 2012 | 780 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 212 | 0.030 |
Why?
| | Rats, Inbred F344 | 1 | 2015 | 256 | 0.030 |
Why?
| | Rats, Inbred WF | 1 | 2014 | 8 | 0.030 |
Why?
| | DNA Methylation | 1 | 2019 | 606 | 0.030 |
Why?
| | Cecum | 1 | 2013 | 32 | 0.030 |
Why?
| | Water Deprivation | 2 | 2003 | 5 | 0.030 |
Why?
| | Pyridones | 1 | 2015 | 158 | 0.030 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1211 | 0.030 |
Why?
| | HeLa Cells | 1 | 2015 | 611 | 0.030 |
Why?
| | Sex Factors | 1 | 2019 | 1966 | 0.030 |
Why?
| | Mice, Mutant Strains | 1 | 2013 | 298 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2827 | 0.030 |
Why?
| | International Cooperation | 1 | 2013 | 177 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 370 | 0.030 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2013 | 97 | 0.030 |
Why?
| | Cardiovascular Diseases | 1 | 2025 | 1997 | 0.030 |
Why?
| | Complement C4b-Binding Protein | 1 | 2012 | 3 | 0.030 |
Why?
| | Coinfection | 1 | 2014 | 131 | 0.020 |
Why?
| | Otitis | 1 | 2012 | 9 | 0.020 |
Why?
| | Hypoxia | 1 | 2020 | 1081 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2012 | 112 | 0.020 |
Why?
| | Ion Transport | 1 | 2012 | 62 | 0.020 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2014 | 146 | 0.020 |
Why?
| | Gene Deletion | 1 | 2014 | 379 | 0.020 |
Why?
| | Gluconeogenesis | 1 | 2012 | 78 | 0.020 |
Why?
| | Demyelinating Diseases | 1 | 2013 | 84 | 0.020 |
Why?
| | Glucose | 1 | 2017 | 996 | 0.020 |
Why?
| | Drug Delivery Systems | 1 | 2015 | 337 | 0.020 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2011 | 23 | 0.020 |
Why?
| | Synovial Fluid | 1 | 2011 | 66 | 0.020 |
Why?
| | Cell Culture Techniques | 1 | 2014 | 347 | 0.020 |
Why?
| | Phosphates | 1 | 2012 | 181 | 0.020 |
Why?
| | Ovalbumin | 1 | 2011 | 177 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2012 | 443 | 0.020 |
Why?
| | Primary Cell Culture | 1 | 2012 | 164 | 0.020 |
Why?
| | Antibodies, Viral | 1 | 2015 | 602 | 0.020 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 169 | 0.020 |
Why?
| | Joints | 1 | 2011 | 101 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2013 | 432 | 0.020 |
Why?
| | Glycolysis | 1 | 2012 | 313 | 0.020 |
Why?
| | Monitoring, Physiologic | 1 | 2012 | 261 | 0.020 |
Why?
| | Mutant Proteins | 1 | 2010 | 100 | 0.020 |
Why?
| | Needs Assessment | 1 | 2012 | 355 | 0.020 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2012 | 541 | 0.020 |
Why?
| | Cartilage | 1 | 2011 | 183 | 0.020 |
Why?
| | Epithelium | 1 | 2011 | 311 | 0.020 |
Why?
| | Glycosylation | 1 | 2010 | 153 | 0.020 |
Why?
| | Amino Acid Substitution | 1 | 2010 | 284 | 0.020 |
Why?
| | Survival Analysis | 1 | 2012 | 1270 | 0.020 |
Why?
| | Chondrocytes | 1 | 2011 | 205 | 0.020 |
Why?
| | Crystallography, X-Ray | 1 | 2010 | 438 | 0.020 |
Why?
| | Zebrafish | 1 | 2013 | 460 | 0.020 |
Why?
| | Molecular Dynamics Simulation | 1 | 2010 | 217 | 0.020 |
Why?
| | Drug Combinations | 1 | 2009 | 329 | 0.020 |
Why?
| | Autoantigens | 1 | 2011 | 420 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 1950 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2011 | 1031 | 0.020 |
Why?
| | Receptors, Interleukin-8B | 1 | 2007 | 24 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 1998 | 1708 | 0.020 |
Why?
| | In Vitro Techniques | 1 | 2010 | 1091 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2010 | 842 | 0.020 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 1 | 2008 | 51 | 0.020 |
Why?
| | Permeability | 1 | 2008 | 158 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 84 | 0.020 |
Why?
| | Biomedical Research | 1 | 2013 | 639 | 0.020 |
Why?
| | Tight Junctions | 1 | 2008 | 75 | 0.020 |
Why?
| | Alleles | 1 | 2010 | 843 | 0.020 |
Why?
| | Mannose-Binding Lectin | 1 | 2007 | 23 | 0.020 |
Why?
| | Microcirculation | 1 | 2007 | 145 | 0.020 |
Why?
| | Cattle | 1 | 2009 | 959 | 0.020 |
Why?
| | Syndrome | 1 | 2007 | 338 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 754 | 0.020 |
Why?
| | Rodentia | 1 | 2006 | 48 | 0.020 |
Why?
| | Placenta Diseases | 1 | 2006 | 15 | 0.020 |
Why?
| | Base Sequence | 1 | 2010 | 2138 | 0.020 |
Why?
| | Vaccination | 1 | 2015 | 1348 | 0.020 |
Why?
| | Antibodies, Antinuclear | 1 | 2006 | 66 | 0.020 |
Why?
| | Methacholine Chloride | 1 | 2006 | 52 | 0.020 |
Why?
| | Protein Transport | 1 | 2008 | 428 | 0.020 |
Why?
| | Head Injuries, Closed | 1 | 2006 | 48 | 0.020 |
Why?
| | fas Receptor | 1 | 2006 | 94 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 1 | 2006 | 70 | 0.020 |
Why?
| | Trachea | 1 | 2007 | 230 | 0.020 |
Why?
| | Synovial Membrane | 1 | 2006 | 91 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2017 | 5078 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2006 | 105 | 0.020 |
Why?
| | Embryo, Mammalian | 1 | 2006 | 224 | 0.020 |
Why?
| | Models, Molecular | 1 | 2010 | 1487 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2012 | 3081 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 298 | 0.010 |
Why?
| | Cell Death | 1 | 2006 | 352 | 0.010 |
Why?
| | Swine | 1 | 2006 | 760 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3058 | 0.010 |
Why?
| | Peptides | 1 | 2009 | 925 | 0.010 |
Why?
| | Receptors, Vasopressin | 1 | 2003 | 19 | 0.010 |
Why?
| | Monocytes | 1 | 2006 | 554 | 0.010 |
Why?
| | Aquaporin 2 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 3 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 6 | 1 | 2003 | 1 | 0.010 |
Why?
| | Aquaporin 1 | 1 | 2003 | 3 | 0.010 |
Why?
| | Psychomotor Performance | 1 | 2006 | 312 | 0.010 |
Why?
| | Kidney Medulla | 1 | 2003 | 34 | 0.010 |
Why?
| | Osmolar Concentration | 1 | 2003 | 167 | 0.010 |
Why?
| | Interleukin-6 | 1 | 2006 | 724 | 0.010 |
Why?
| | Cell Survival | 1 | 2006 | 1084 | 0.010 |
Why?
| | Behavior, Animal | 1 | 2006 | 495 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1717 | 0.010 |
Why?
| | Aquaporin 4 | 1 | 2003 | 95 | 0.010 |
Why?
| | Gene Expression Regulation | 1 | 2011 | 2544 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2006 | 2013 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 2009 | 1018 | 0.010 |
Why?
| | Neoplasms | 1 | 2015 | 2450 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2003 | 477 | 0.010 |
Why?
| | Placenta | 1 | 2006 | 716 | 0.010 |
Why?
| | Asthma | 1 | 2011 | 2225 | 0.010 |
Why?
| | Transients and Migrants | 1 | 1998 | 26 | 0.010 |
Why?
| | Brazil | 1 | 1998 | 154 | 0.010 |
Why?
| | Age Distribution | 1 | 1998 | 371 | 0.010 |
Why?
|
|
Thurman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|